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We present a prognostic model for metastatic renal cell carcinoma based on fractional polynomials. We retrospectively analysed 425
metastatic renal cell carcinoma patients treated with subcutaneous recombinant cytokine-based home therapies in consecutive trials.
In our approach, we categorised a continuous prognostic index produced by the multivariable fractional polynomial (MFP) algorithm,
using a strategy in which continuous predictors are kept continuous. The MFP algorithm selected five prognostic factors as significant
at the 5% level in a multivariable model: lymph node metastases, liver metastases, bone metastases, age, C-reactive protein and
neutrophils. The MFP model allowed us to divide patients into four risk groups achieving median overall survivals of 38 months (low
risk), 23 months (low intermediate risk), 15 months (high intermediate risk) and 5.6 months (high risk). Our approach, based on
categorising a continuous prognostic index produced by the MFP algorithm, allowed more flexibility in the determination of risk
groups than traditional approaches.
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For renal cell carcinoma, certain prognostic staging factors,
notably, performance status, disease-free interval, erythrocyte
sedimentation rate (ESR), lactate dehydrogenase (LDH), neutro-
phils, haemoglobin, extrapulmonary and bone metastases, and
number of metastatic sites were identified as prognostic factors for
survival (Elson et al, 1988; Palmer et al, 1992; Lopez-Ha ¨nninen
et al, 1996; Gelb, 1997; Culine et al, 1998; Hoffmann et al, 1999;
Motzer et al, 1999, 2002; Atzpodien et al, 2003).
However, the importance of each predictor varies from study to
study and is, therefore, controversial. Besides heterogeneity in
patient populations and treatments between different studies, a
substantial reason for the observed variation might be attributable to
an inadequate use of statistical methods (Simon and Altman, 1994).
Most researchers who develop and publish prognostic models in
cancer seem to assume that to introduce continuous predictors,
such as age and haemoglobin, into a multivariable statistical
model, it is necessary first to ‘categorise’ the predictors into two
groups. However, the choice of an appropriate cutpoint is not
usually obvious a priori. To avert the worry that an arbitrary
choice may be sub-optimal, there have been strategies searching
for the ‘optimal’ cutpoint for each continuous predictor, thus,
yielding the smallest P-value when testing the effect of the
categorised predictor in a univariate Cox model or log-rank
analysis. Once such a set of cutpoints has been found, the final
multivariable model is often determined by applying a standard
algorithm, such as stepwise selection of variables, to the candidate
predictors. Sometimes, only those individually significant at the
5% level are considered as candidates for inclusion in the
multivariable model.
The disadvantages of such a modelling strategy have been
rehearsed quite often in the statistical literature. Here, we will
illustrate an alternative strategy in which continuous predictors are
kept continuous, and in which, furthermore, nonlinear relation-
ships (if present) are detected and modelled appropriately. As it is
clearly sensible to derive prognostic groups for clinical purposes
and for displaying results, the final step of our approach is to
categorise the prognostic index from the final model and to
compare it with a traditional approach based on categorised
covariates (Atzpodien et al, 2003).
PATIENTS AND METHODS
Patients
A total of 425 patients with progressive metastatic renal cell
carcinoma were entered into consecutive clinical trials between
November 1988 and February 1998 to receive either (A) IFN-a2a,
IL-2 (n¼102pts), (B) IFN-a2a, IL-2 and 5-FU (n¼235pts) or (C)
IFN-a2a, IL-2 and 5-FU combined with 13cRA (n¼88pts)
(Atzpodien et al, 2003). Median follow-up of these patients was
20þ months (range 0 157þ months). Patient pretreatment
included radical tumour nephrectomy (n¼412), chemotherapy
(n¼5), immunotherapy (n¼47), chemoimmunotherapy (n¼8),
and hormone therapy (n¼32).
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sCriteria for entry into the study were histologically confirmed
metastatic renal cell carcinoma, an expected survival duration of
more than 3 months, Karnofsky performance status 480%, age
between 18 and 80 years, white blood cell count 43500ml
 1,
platelet count 4100000ml
 1, hematocrit 430%, serum bilirubin
and creatinin o1.25 of the upper normal limit. Exclusion criteria
included evidence of congestive heart failure, severe coronary
artery disease, cardiac arrhythmias, symptomatic central nervous
system (CNS) disease or seizure disorders, human immunodefi-
ciency virus infections or positivity for hepatitis B surface antigen
or chronic hepatitis, or concomitant corticosteroid therapy. In all
patients treated, no chemotherapy, immunomodulatory treatment
or steroid therapy had been performed during the previous
4 weeks. Pregnant and lactating woman were excluded.
The clinical studies were approved by the institutional review
board of the Medizinische Hochschule Hannover; written informed
consent was obtained from all patients before entry into the study.
Treatment design
Treatment regimens were designed to be administered in the
outpatient setting. All patients received outpatient subcutaneous
(s.c.) IFN-a2a and s.c. IL-2. Treatment A consisted of s.c. rIFN-a2a
(Roferon
s, Hoffmann-La Roche; Grenzach-Wyhlen, Germany)
(5 10
6IUm
 2, day 1, weeks 1þ4; days 1, 3, 5, weeks 2, 3, 5, 6 and
s.c. rIL-2 (Proleukin
s, Chiron, Emeryville)) (10 10
6IUm
 2,
twice daily days 3–5, weeks 1þ4; 5 10
6IUm
 2, days 1, 3, 5,
weeks 2, 3, 5, 6), only; weeks 7 and 8 were therapy-free. Treatment
B consisted of IFN-a2a (5 10
6IUm
 2, day 1, weeks 1þ4; days 1,
3, 5, weeks 2þ3; 10 10
6IUm
 2, days 1, 3, 5, weeks 5–8), IL-2 s.c.
rIL-2 (10 10
6IUm
 2, twice daily days 3–5, weeks 1þ4;
5 10
6IUm
 2, days 1, 3, 5, weeks 2þ3) and intravenous (i.v.)
5-FU (1000mgm
 2, day 1, weeks 5–8 (Atzpodien et al, 2004)).
Treatment C consisted of treatment arm B combined with po
13cRA (20mg 2 daily over 8 weeks). Eight-week treatment cycles
were repeated for up to three courses unless progression of disease
occurred. Concomitant medication was given as needed to control
adverse effects of chemoimmunotherapy.
Fractional polynomials
Fractional polynomials were introduced by Royston and Altman
(1994) as an extension of the familiar and well-established
polynomial method of modelling with continuous predictors.
The aim was to increase the range of functions that could be
represented, while maintaining simplicity and mathematical
tractability. We will denote by x a continuous prognostic factor.
By transforming x, the first-order polynomial (i.e. linear function)
y ¼ a þ bx
is extended to the first-order fractional polynomial or FP1 function
y ¼ a þ bxp:
For technical reasons the power p is restricted to the special set  2,
 1,  1/2, 0, 1/2, 1, 2, 3. Here ‘x
0’ denotes the natural log
function, log(x). The second order or quadratic polynomial
y ¼ a þ bx þ cx2
is extended to the second order fractional polynomial or FP2
function
y ¼ a þ bxp þ cxq
or
y ¼ a þ bxp þ cxp logðxÞ
the second form being known as a ‘repeated powers’ model.
Royston and Altman (1994) demonstrated that by varying the
powers (p,q) and the coefficients (b,c), a remarkable range of
curve shapes could be created from these simple families of
mathematical functions. This imparts great flexibility for model-
ling nonlinear relationships in real data. Note that linear and
quadratic polynomials are special cases of the more general FP1
and FP2 fractional polynomials.
Technical details of how a fractional polynomial model for one
predictor x is determined (that is, how the powers are estimated)
and how significance testing is done will not be given here;
interested readers are referred to Royston and Altman (1994). An
introduction to fractional polynomials in the context of estimating
the prognosis of breast cancer patients is given by Sauerbrei et al
(1999).
Multivariable modelling with fractional polynomials
Sauerbrei and Royston (1999) developed the MFP (multivariable
fractional polynomial) approach to building models from several
predictors of which at least one is continuous. They exemplified
the method in prognostic and diagnostic modelling in breast
cancer.
Thus, we first specify a nominal P-value for testing for inclusion
of variables and for determining the complexity of the functional
form for all continuous predictors. The conventional 0.05 level was
used. The algorithm then works in an iterative fashion, sorting out
which are the significant predictors and how much simplification
of the functional forms can be made at the given significance level.
The simplest function for a given continuous predictor is a straight
line, and this is chosen by default if there is no convincing
evidence of nonlinearity.
The final model in survival analysis can then be used to produce
a prognostic index or risk score, which is a weighted combination
of the predictors with weights (regression coefficients) taken from
the Cox model. The prognostic index value for a given individual
summarises the relative hazard of that person with respect to a
hypothetical patient with predictor values all equal to zero. If a
fractional polynomial is required for any predictor, that function
was used when calculating the prognostic index.
An example of the form of a prognostic index for three variables
x1, x2, x3 is as follows:
PI ¼ ax1 þ bx2 þ c=x3 þ dlogðx3Þ:
Here, the continuous predictor x3 has been transformed with an
FP2 function with powers  1, 0, whereas the other two predictors
are included as linear functions. The constants a, b, c and d are
determined by fitting the Cox model to the data in the usual way.
Software to run the MFP algorithm is available in the packages
Stata, SAS and R (see Sauerbrei et al, 2006 for details).
Survival was measured from start of therapy to date of death or
to the last date known to be alive. Survival curves were estimated
by the Kaplan–Meier method.
RESULTS
We constructed a prognostic model based on a study of 425
metastatic renal cell carcinoma patients using fractional poly-
nomials.
Six binary (sex, lung, lymph node, liver, bone, brain/CNS
metastases) and eight continuous (age, time from diagnosis to
metastatic disease, number of metastatic sites, ESR, C-reactive
protein (CRP), haemoglobin, neutrophils, LDH) predictors were
included in univariate FP analysis.
The MFP algorithm selected five prognostic factors as significant
at the 5% level in a multivariable model: lymph node metastases,
liver metastases, bone metastases, age, CRP and neutrophils
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s(Table 1). C-reactive protein was subject to an FP1 transformation
with power  2.
Figure 1 shows the survival curves when the patients were
divided into four risk groups. These were chosen by applying
cutpoints to the prognostic index at the 10th, 50th and 90th
centiles, for the subset of patients who experienced an event (i.e.
who died). The formula for the prognostic index from the final Cox
model was as follows:
PI ¼ 0:0178 age þ 0:3325 lymphnodes
þ 0:2967 liver þ 0:5469 bone   10:63=CRP2
þ 0:0001001 neutrophils;
where ‘lymphnodes’ takes the value 1 for patients with lymph node
metastases and 0 for patients without lymph node metastases,
similarly ‘liver’ for liver metastases and ‘bone’ for bone metastases.
The cutpoints to divide the patients into the four prognostic
groups are  0.986,  0.476 and 0.147. For example, consider a
patient aged 50years, with lymph node metastases but no liver and
bone metastasis, CRP 23mgl
 1 and neutrophils 3000(cellsml
 1).
The PI is  0.0178 50þ0.3325 1þ0.2967 0þ0.5469 0–
10.63/23
2þ0.0001001 3000¼ 0.2772 placing them in risk
group 3 (between the 50th and 90th centiles of risk).
Median overall survival for low (n¼51), low intermediate
(n¼172), high intermediate (n¼164), and high-risk (n¼38)
patients was 38 months (95% CI: 24, 53), 23 months (95% CI: 20,
27), 15 months (95% CI: 13, 20), and 5.6 months (95% CI: 4.5, 7.9),
respectively (Table 2).
DISCUSSION
During recent years, many prognostic factors (clinicopathological,
biological, molecular) have been investigated to construct prog-
nostic models that predict the clinical course of renal cell
carcinoma patients (Elson et al, 1988; Motzer et al, 2002;
Atzpodien et al, 2003). However, the importance of individual
factors is controversial. One important reason for this concerns the
inadequate use of statistical methods for continuous predictors,
such as age or haemoglobin, finally leading to difficulties in
comparing multivariable models with different categorisations of
the factors (Simon and Altman, 1994).
Although our retrospective data set did not fully comply with
the recent publication of REMARK guidelines for prognostic
studies (McShane et al, 2005), here, we illustrated an alternative
and very effective method for selecting a prognostic model in
which continuous predictors are kept continuous, and in which,
nonlinear relationships are detected and modelled appropriately
by using fractional polynomials.
Based on our data set of 425 metastatic renal cell carcinoma
patients, the MFP algorithm selected six prognostic factors as
significant at the 5% level in a multivariable model: lymph node
metastases, liver metastases, bone metastases, age, CRP and
neutrophils. The model of Atzpodien et al (2003) based on the
same data set but using the log-rank test for categorical variables
and a score based on Cox proportional hazards model, had in
common the predictors CRP, neutrophils and bone metastases;
however, they excluded age, lymph node metastases and liver
metastases and included instead LDH, time from diagnosis to
metastatic disease, and number of metastatic sites. The last three
predictors, according to the MFP algorithm presented here, had
P-values of 0.1, 0.5 and 0.09, respectively, after including the six
significant factors.
The beauty of developing a continuous prognostic index, as
presented here, is that it provides enormous flexibility in creating
risk groups. The sample of patients may be divided into any
number of equal or unequal groups. The only major caveat is
that creating a large number of groups is unlikely to reliably
divide the population into such fine risk strata. Usually no more
than three or at most four groups should be produced. Thus, we
divided the patients into four risk groups chosen by applying
cutpoints to the prognostic index at the 10th, 50th and 90th
centiles, for the subset of patients who experienced an event (i.e.
who died). Evening out the number of events in this way tends to
give more reliable risk estimates, as the number of events is the
effective sample size in a survival analysis. Low (n¼51), low
Table 1 The MFP algorithm applied to the renal cancer data set
Predictor
In/out
of
model P-value
a
FP
transformation
Binary
Sex Out 0.8
Lung metastases Out 0.9
Lymph node metastases In 0.005 N/A
Liver metastases In 0.05 N/A
Bone metastases In o0.001 N/A
Brain/CNS metastases Out 0.2
Continuous
Age In 0.02 Linear
Time from diagnosis to
metastatic disease
Out 0.4
Number of metastatic sites Out 0.3
ESR Out 0.3
CRP In 0.01 FP1 ( 2)
Haemoglobin Out 0.6
Neutrophils In 0.001 Linear
LDH Out 0.2
aAt final cycle of the MFP algorithm. CNS¼central nervous system, CRP¼C-
reactive protein, ESR¼erythrocyte sedimentation rate, LDH¼lactate dehydrogen-
ase, MFP¼multivariable fractional polynomial.
168 156 144 132 120 108 96 84 72 60 48 36 24 12 0
p
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B: low intermediate risk 
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Figure 1 Kaplan–Meier curves for four risk groups based on prognostic
index from MFP model. Groups contain 10, 40, 40 and 10% of events,
respectively.
Table 2 Median survival by risk group from the MFP model
Risk Group
Number of
patients/deaths
Median survival
(months)
95% confidence
interval
Low 51/37 38 24, 53
Low intermediate 172/149 23 20, 27
High intermediate 164/148 15 13, 20
High 38/37 5.6 4.5, 7.9
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risk (n¼38) patients exhibited a median overall survival of
38 months, 23 months, 15 months and 5.6 months, respectively.
In comparison, the median survival times for the three risk
groups derived from the same data set by Atzpodien et al (2003)
were 32 months (low risk), 18 months (intermediate risk) and
8 months (high risk).
A measure of prognostic discrimination that is sometimes
advocated is the c-index (Harrell 2001, p. 493), a generalisation for
survival data of the area under the receiver–operator characteristic
(ROC) curve. The three-group classification of Atzpodien et al
(2003) had a c-index of 0.628, compared with 0.632 for the model
derived by the MFP algorithm. The discrimination is therefore
much the same between the two models. According to the measure
of explained variation proposed by Royston and Sauerbrei (2004),
the R
2 values for these two models are both 0.11.
In conclusion, the method based on a continuous prognostic
index was apparently able to refine the classification of survival
times in the present renal cell carcinoma patients. Although, in our
data set the prognostic capacity of the two models was similar, the
approach based on categorising a continuous prognostic index
produced by the MFP algorithm allowed more flexibility in the
determination of risk groups.
It should be noted, though, that the present data set was of good
performance status patients, fit enough for immunotherapy. The
results are not necessarily generalisable to the whole population of
metastatic renal cell cancer patients. The acid test of any model is
its ability to predict well in independent data. As a data set with
similar prognostic factors measured was not available to us, we
could not yet evaluate the generalisability of the two models.
Validation of our proposed model will require testing in a
prospectively designed study of a wider patient population.
REFERENCES
Atzpodien J, Royston P, Reitz M (2003) Metastatic renal carcinoma
extended staging system. Br J Cancer 88(3): 348–353
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H,
Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S,
Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger
T, Reitz M (2004) Prospectively Randomized Trial of the German
Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
J Clin Oncol 22(7): 1188–1194
Culine S, Bekradda M, Kramar A, Rey A, Escudier B, Droz JP (1998)
Prognostic factors for survival in patients with brain metastases from
renal cell carcinoma. Cancer 83(12): 2548–2553
Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in
patients with recurrent or metastatic renal cell carcinoma. Cancer Res
48(24 Part 1): 7310–7313
Gelb AB (1997) Renal cell carcinoma: current prognostic factors. Union
Internationale Contre le Cancer (UIC) and American Joint Committee on
Cancer (AJCC). Cancer 80(5): 981–986
Harrell Jr FE (2001) Regression Modelling Strategies. New York: Springer,
p 493
Hoffmann R, Franzke A, Buer J, Sel S, Oevermann K, Duensing A, Probst M,
Duensing S, Kirchner H, Ganser A, Atzpodien J (1999) Prognostic impact
of in vivo soluble cell adhesion molecules in metastatic renal cell
carcinoma. Br J Cancer 79(11–12): 1742–1745
Lopez-Ha ¨nninen E, Kirchner H, Atzpodien J (1996) Interleukin-2-based
home therapy of metastatic renal cell carcinoma: risks and benefits in
215 consecutive single institution patients. J Urol 155: 19–25
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, for
the Statistics Subcommittee of the NCI-EORTC Working Group on
Cancer Diagnostics (2005) REporting recommendations for tumour
MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2(8):
416–422
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-
alpha as a comparative treatment for clinical trials of new therapies
against advanced renal cell carcinoma. J Clin Oncol 20(1): 289–296
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999)
Survival and prognostic stratification of 670 patients with advanced renal
cell carcinoma. J Clin Oncol 17(8): 2530–2540
Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R,
Francs CR (1992) Prognostic factors for survival in patients with
advanced renal cell carcinoma treated with recombined interleukin-2.
Annu Oncol 3(6): 475–480
Royston P, Altman DG (1994) Regression using fractional polynomials
of continuous covariates: parsimonious parametric modelling (with
Discussion). Appl Stat 43: 429–467
Royston P, Sauerbrei W (2004) A new measure of prognostic separation in
survival data. Stat Med 23: 723–748
Sauerbrei W, Meier-Hirmer C, Benner A, Royston P (2006) Multivariable
regression models by using fractional polynomials: description of SAS,
Stata and R programs. Comput Stat Data Anal (in press)
Sauerbrei W, Royston P (1999) Building multivariable prognostic and
diagnostic models: transformation of the predictors by using fractional
polynomials. J R Stat Soc (Ser A) 162: 71–94
Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M, the German
Breast Cancer Study Group (1999) Modelling the effects of standard
prognostic factors in node positive breast cancer. Br J Cancer 79:
1752–1760
Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies
in oncology. Br J Cancer 69: 979–985
Estimating prognosis using fractional polynomials
P Royston et al
1788
British Journal of Cancer (2006) 94(12), 1785–1788 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s